PSIL stock forecast, quote, news & analysis

Key Takeaways

• PSIL is an actively managed thematic ETF providing exposure to the emerging global psychedelic-medicine industry, with essentially all of its portfolio concentrated in the healthcare sector.
• The fund holds roughly 30 to 35 mostly small- and micro-cap life sciences companies, with Compass Pathways, Definium Therapeutics, Atai Beckley, Relmada Therapeutics, and NRx Pharmaceuticals among its largest positions.
• PSIL declined approximately 9% over the trailing month, reflecting a broad pullback across speculative biotech and small-cap growth names.
• The fund carries a net expense ratio of approximately 1.00% and a non-diversified structure, consistent with a niche, actively managed thematic vehicle.
• Elevated interest rates and a risk-off tone toward pre-revenue biotechnology remain the dominant macro headwinds for the strategy.
• Key risks include binary clinical-trial outcomes, regulatory uncertainty, and limited liquidity in underlying holdings.
• For additional detail on this ticker, explore PSIL Price Targets and Forecast.
• Discover more ideas with Trending AI Robots.

AdvisorShares Psychedelics ETF (PSIL) Overview

The AdvisorShares Psychedelics ETF is an actively managed exchange-traded fund (ETF) launched in September 2021. Under normal circumstances, the fund invests at least 80% of its net assets in securities of companies that derive a meaningful share of revenue from, or devote substantial assets to, psychedelic drugs, alongside derivatives with similar economic characteristics. The portfolio primarily targets publicly listed life sciences companies developing psychedelic medicines, but it also includes related businesses operating across the broader psychedelics ecosystem.

PSIL is a non-diversified, single-sector vehicle with effectively 100% of assets allocated to healthcare. It holds roughly 30 to 35 positions, blending pure-play psychedelic drug developers with larger, more established pharmaceutical companies. Core holdings have included Compass Pathways, Definium Therapeutics, Atai Beckley, Relmada Therapeutics, and NRx Pharmaceuticals, alongside positions in companies such as Neurocrine Biosciences, Cybin, and GH Research. The net expense ratio is approximately 1.00%. Given the small average market capitalization of its underlying names, PSIL behaves more like a concentrated, early-stage biotech portfolio than a broad equity fund.

Industry and Thematic Landscape

The psychedelic-medicine theme sits at the intersection of psychiatry, neuroscience, and novel drug development. Companies in this space are pursuing therapies derived from compounds such as psilocybin, MDMA, and related molecules to treat conditions including treatment-resistant depression, post-traumatic stress disorder, and other mental-health disorders. The investment case rests on a sizable unmet clinical need and early, often promising, trial data, but commercialization remains largely unproven.

The broader environment has been challenging for early-stage biotechnology. Higher-for-longer interest rates reduce the present value of distant cash flows and raise the cost of capital, pressuring pre-revenue companies that depend on equity financing to fund multi-year clinical programs. Regulatory review of psychedelic compounds has also been uneven, with mixed clinical outcomes and cautious signals from health authorities. These structural factors mean the theme is characterized by high volatility, binary catalysts, and concentrated risk rather than steady, diversified growth.

Performance and Positioning Snapshot

PSIL has been volatile over recent months. After a rally that carried the fund toward a late-summer peak around $27, the ETF gave back much of its 2026 gains and declined roughly 9% over the trailing month to trade near $21. The move has been trend-driven rather than range-bound, reflecting a broader de-rating of speculative, small-cap biotech rather than fund-specific news.

Because the portfolio is concentrated in a handful of clinical-stage developers, its performance has been closely tied to the fortunes of its largest holdings. Compass Pathways and Atai Beckley, both leaders in psilocybin and other psychedelic programs, and smaller developers such as Relmada Therapeutics have experienced pronounced swings as trial readouts, financing activity, and shifting investor sentiment reshaped expectations. The presence of larger pharmaceutical names provides only limited ballast given the small size of the overall fund and the dominance of the healthcare theme.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. The tool is designed to surface trending securities, breakout candidates, and emerging trading opportunities more efficiently than manual screening, allowing users to narrow the investable universe by industry, performance characteristics, and quantitative criteria. For investors researching niche, fast-moving themes such as psychedelic medicine, an automated discovery workflow can help identify relevant names more quickly. Explore the AI Screener to begin scanning the market with AI-assisted tools.

2026 Outlook and Key Factors to Monitor

The trajectory of PSIL over the remainder of 2026 will likely hinge on several structural factors. Clinical trial results and regulatory decisions for psychedelic-based therapies remain the most consequential catalysts, as positive data could re-rate the entire theme while disappointing outcomes carry concentrated downside risk. The interest-rate environment and the availability of capital for early-stage biotech will continue to shape financing conditions for portfolio companies, many of which require repeated equity raises.

Investors should also monitor regulatory policy toward psychedelic compounds, competitive developments among leading developers, and the potential for consolidation as larger pharmaceutical companies evaluate the space. Institutional fund flows into thematic and biotech ETFs, alongside overall risk appetite, will influence near-term price action. While the long-term addressable market in mental health is substantial, the path to commercialization is uncertain, and the fund's concentrated, non-diversified structure amplifies both the opportunity and the risk. No price predictions are made here; these are simply the key themes likely to drive the ETF in the months ahead.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations